Metoprolol Succinat Teva

Metoprolol, the active ingredient in Metoprolol Succinat Teva, is a beta‑adrenergic blocker presented as an oral tablet for oral use. It is used to manage high blood pressure, angina, heart failure, and certain cardiac arrhythmias in adult patients.

GNH USA supplies Metoprolol Succinat Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from comprehensive regulatory support and consistent product availability across multiple markets.

Metoprolol acts on the cardiovascular system to lower blood pressure and reduce myocardial oxygen demand, making it useful for several cardiac conditions.

Hypertension: lowers systemic blood pressure and reduces risk of cardiovascular events. Chronic stable angina: decreases frequency of chest‑pain episodes by improving myocardial oxygen balance. Heart failure (reduced ejection fraction): improves survival and reduces hospitalizations by decreasing cardiac workload. Post‑myocardial infarction: helps prevent recurrent ischemic events and supports cardiac remodeling. Atrial and ventricular arrhythmias: stabilizes heart rhythm by slowing conduction through the AV node.

Metoprolol may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Fatigue: feeling of tiredness or lack of energy. - Dizziness or light‑headedness: especially when standing quickly. - Cold extremities: reduced blood flow to hands and feet. - Gastrointestinal upset: nausea, abdominal discomfort or constipation. - Sleep disturbances: insomnia or vivid dreams.

Serious or Rare Side Effects: - Bradycardia: abnormally slow heart rate that may require medical attention. - Severe hypotension: dangerously low blood pressure causing fainting. - Heart block: impaired electrical conduction in the heart. - Bronchospasm: narrowing of airways, particularly in patients with asthma. - Depression or mood changes: new or worsening depressive symptoms.

When prescribing Metoprolol, clinicians should consider several safety precautions to minimize risk.

- Assess cardiovascular status: evaluate heart rate, blood pressure and cardiac function before initiation. - Review respiratory conditions: use cautiously in patients with asthma or chronic obstructive pulmonary disease. - Monitor glucose control: beta‑blockers may mask hypoglycemia symptoms in diabetic patients. - Adjust for renal or hepatic impairment: dose may need modification in reduced organ function. - Avoid abrupt discontinuation: taper gradually to prevent rebound tachycardia or hypertension. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Metoprolol can interact with other medicines, altering its effectiveness or increasing adverse effects.

Major Interactions (Avoid): - Non‑selective beta‑blockers with calcium channel blockers (e.g., verapamil, diltiazem): may cause severe bradycardia or heart block. - Antidiabetic agents (insulin, sulfonylureas): increased risk of hypoglycemia due to masked symptoms. - Antidepressants (e.g., MAO inhibitors): can enhance hypotensive effects.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: additive blood pressure lowering may require monitoring. - Antithyroid drugs (e.g., propylthiouracil): may reduce the heart‑rate‑lowering effect. - NSAIDs: may diminish antihypertensive efficacy.